Report Highlights

U.S. HAE Therapeutics: Competitive Overview

The U.S. HAE therapeutics market is moderately concentrated, with Takeda and CSL Behring together holding the majority of branded revenue across prophylaxis and acute treatment. Takeda's Takhzyro (lanadelumab), Firazyr (icatibant), and Cinryze sit alongside CSL Behring's Berinert and Haegarda, giving both companies deep allergist and immunologist relationships. Newer entrants are fragmenting the field at the margins, but scale in specialty pharmacy contracting still favors incumbents.

Domestic players are rare; the market is led by multinationals headquartered in Japan, Australia, and Europe, while American firms BioCryst, KalVista, and Ionis win share through oral and antisense modalities. Competitive advantage here depends less on molecule efficacy than on payer access, specialty pharmacy distribution, and funding long-term patient support programs for roughly 7,000 diagnosed patients. Scale in these areas determines which companies survive the forecast period.

Demand Drivers Shaping U.S. HAE Therapeutics

Rising diagnosis rates are the first driver, as C1-INH function testing and genetic panels move into allergist and emergency department workflows. Takeda benefits most, since lanadelumab's every-two-week dosing and established prescriber base capture newly diagnosed prophylaxis patients. Second, growing emergency department awareness of laryngeal attacks lifts demand for fast on-demand therapy, favoring firms with at-home formulations and oral options. Generic icatibant from Fresenius Kabi captures much of the price-sensitive hospital volume.

Third, payer scrutiny of high-cost biologics is pushing patients toward lower-cost oral prophylaxis under employer-sponsored and Medicare Part D plans. BioCryst's Orladeyo, dosed as a daily tablet, benefits most from this shift and from avoiding infusion-center visits. Pharmacy benefit managers increasingly favor preferred oral agents on formulary tiers that reward lower net cost per patient. Manufacturers that bundle on-demand and prophylaxis programs with copay assistance and nurse support will convert step-therapy patients fastest.

Competitive Restraints and Market Challenges

Price competition is intensifying in on-demand therapy, where generic icatibant from Fresenius Kabi and Teva has compressed net prices and pushed branded Firazyr into rebate-heavy contracts. Pharmacy benefit managers including CVS Caremark, Express Scripts, and OptumRx use exclusion lists to force brand switching. Each new launch therefore carries a rebate cost that erodes manufacturer margins before patient volume materializes. Smaller companies without scale rebate leverage face the steepest margin pressure.

Talent and infrastructure constraints compound the problem. Only a limited number of allergists and immunologists treat HAE at scale, and genetic counseling capacity remains thin outside major academic centers. Specialty pharmacy concentration among a few dispensers, combined with cold-chain requirements for plasma-derived C1-INH products, adds operating costs that smaller entrants struggle to absorb. Payer-mandated prior authorization adds administrative staffing burdens that rare-disease teams must fund.

Growth Opportunities for Market Players

Pediatric HAE represents an underserved opportunity, since most prophylaxis labels remain narrow and long-term safety data for younger children is limited. Companies that generate pediatric pharmacokinetic and safety evidence early can secure formulary position before competitors. Astria Therapeutics' long-acting navenibart, designed for less frequent dosing, is positioned to capture families seeking fewer injections.

Home-based and telehealth delivery form a second opening, as patients who self-administer subcutaneous or oral therapies reduce dependence on infusion centers. CSL Behring's Haegarda and Takeda's lanadelumab programs already offer nurse-led onboarding, and digital adherence tracking can differentiate further. Players that connect specialty pharmacy dispensing, home delivery, and telehealth allergy consults will capture the adherence-driven share that payers reward.

Market at a Glance

Leading Market Participants

• Takeda Pharmaceuticals
• CSL Behring
• BioCryst Pharmaceuticals
• KalVista Pharmaceuticals
• Pharvaris
• Ionis Pharmaceuticals
• Pharming Group
• Astria Therapeutics
• Fresenius Kabi
• Teva Pharmaceuticals

Regulatory and Policy Environment

FDA's Center for Drug Evaluation and Research regulates oral small molecules such as berotralstat and sebetralstat, while the Center for Biologics Evaluation and Research oversees plasma-derived and recombinant C1-INH products under biologics license applications. Icatibant generics follow Hatch-Waxman abbreviated approval pathways, enabling price competition that biologic competitors do not face. Orphan drug designation grants seven years of market exclusivity, shaping how first movers defend their franchises.

The Inflation Reduction Act's Medicare drug price negotiation program and its orphan drug exclusion shape investment decisions for rare-disease products, with the exclusion expanded by 2025 legislation. State step-therapy laws and the federal Anti-Kickback Statute govern how manufacturers fund patient support programs and copay assistance. Section 340B contract pharmacy rules further determine which specialty pharmacies capture HAE volume and at what margin.

Competitive Outlook for U.S. HAE Therapeutics

By 2032, the U.S. market will shift from injectable dominance toward a multi-modal structure, with oral prophylaxis and on-demand tablets capturing a growing share of new-start patients. Takeda will retain the largest revenue share through lanadelumab's entrenched prescriber base, while BioCryst and KalVista gain ground as tablets become the default for convenience-driven patients. Pharvaris's deucrictibant adds a third oral on-demand contender as its pivotal program advances.

Consolidation is the second structural force, as mid-size developers without a second-generation product face acquisition pressure. Ionis, Pharvaris, and Astria Therapeutics are attractive targets for multinationals seeking pipeline depth in rare immunology. Generic icatibant volume will become a commodity business dominated by Fresenius Kabi and Teva, leaving branded innovators to compete on access, adherence, and convenience.